Fennec Pharmaceuticals (FENC)
Commercializes PEDMARK for pediatric cisplatin-related hearing-loss protection.
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Adherex Technologies (FENC) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q2 2026 Earnings Call Transcript
Adherex Technologies Q2 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
Fennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2026 financial results before the opening of the U.S. financial markets on Tuesday, August 11, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
Adherex Technologies Inc. (NASDAQ:FENC) Receives Consensus Rating of “Moderate Buy” from Analysts
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have given a buy recommendation and one
Is the Options Market Predicting a Spike in Adherex Technologies Stock?
Investors need to pay close attention to FENC stock based on the movements in the options market lately.
Fennec Announces Results of Annual Meeting
RESEARCH TRIANGLE PARK, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 28, 2026 were elected as directors of the Company at the Annual General and Special Meeting of Shareholders held online on June 10, 2025.
Adherex Technologies' PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals NASDAQ: FENC executives outlined the company's commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference.
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Fennec Pharmaceuticals Inc. (FENC) Q1 2026 Earnings Call Transcript
Adherex Technologies Q1 Earnings Call Highlights
Adherex Technologies NASDAQ: FENC executives said Fennec Pharmaceuticals entered 2026 with stronger commercial momentum for PEDMARK, reporting higher first-quarter sales, positive operating cash flow and early signs that recent sales force investments are increasing demand.
Adherex Technologies Inc. (FENC) Beats Q1 Earnings and Revenue Estimates
Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.04 per share a year ago.
Fennec Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~ Achieved First Quarter 2026 Total Net Revenues of $15.1 Million, Up 73% Year Over Year ~ ~ Field Sales Expansion Showing Early Signs of Positive Results with Record PEDMARK ® Demand in April 2026 ~ ~ Initiated Third Institution-Led Clinical Study Evaluating PEDMARK ® in Adolescent and Young Adult (AYA) and Adult Patients with Head and Neck and Testicular Cancers ~ ~ Four Abstracts Evaluating PEDMARK ® will be Included in the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Program ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C.
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2026 financial results before the opening of the U.S. financial markets on Thursday, May 14, 2026. Management will host a conference call and webcast that day to discuss the Company's financial and business results.
FENC Secures Second Consecutive Inclusion in S&P Global Dow Jones Best in Class Emerging Markets Index
TAIPEI, May 6, 2026 /PRNewswire/ -- Far Eastern New Century Corporation ("FENC" or "the Company") has once again been selected as a constituent of S&P Global 2026 Dow Jones Best in Class (DJBIC) Emerging Markets Index, standing out among approximately 3,500 invited companies worldwide. This marks the second consecutive year that FENC has been included in the index, underscoring the Company's solid performance in sustainability practices and risk management capabilities.
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Adherex Technologies Inc. (NASDAQ:FENC) Receives Average Rating of “Moderate Buy” from Brokerages
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to
Adherex Technologies (FENC) to Release Earnings on Wednesday
Adherex Technologies (NASDAQ: FENC - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of $0.0423 per share and revenue of $14.7490 million for the quarter. Individuals can check the company's upcoming Q4 2025 earning summary page for
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigation focuses on Fennec Pharmaceuticals executive officers and whether investor losses may be recovered under federal securities laws.